[Gold-induced fibrosing alveolitis].
Fibrotic alveolitis appeared in a 54-year-old patient undergoing gold therapy. In differential diagnosis, this infrequent side effect of gold therapy is to be distinguished from rheumatoid lung fibrosis. Lymphocyte sub-populations were determined in the broncho-alveolar lavage fluid of the patient. The results obtained support the view that the side effect is due to an immunologically mediated process.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004417:Dyspnea / Q000209:etiology; D006046:Gold / Q000009:adverse effects* / Q000627:therapeutic use; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D012129:Respiratory Function Tests; D013601:T-Lymphocytes / Q000145:classification
D000949:Histocompatibility Antigens Class II; D006046:Gold; D011241:Prednisone
Gold-induzierte fibrosierende Alveolitis.